Real world study of chemoimmunotherapy for treatment of aggressive B-cell lymphomas.
Home / Resource Library / Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study